Aicardi–Goutières syndrome

Lore & Background

The initial description of AGS in 1984 suggested a uniformly severe disease with unremitting neurological decline and death in childhood. However, as more cases were identified, it became apparent that the clinical picture is broader: many patients demonstrate a stable course into their fourth decade, and rare individuals with pathogenic mutations are minimally affected, sometimes only with chilblains, and attend mainstream education. Even siblings with identical mutations can show marked differences in severity.

About ten percent of cases present at or soon after birth with microcephaly, neonatal seizures, cerebral calcifications, and white matter abnormalities, indicating in utero onset. Approximately one third of these early-presenting cases, most often with TREX1 mutations, die in early childhood. The majority of cases present in early infancy with encephalopathy, irritability, feeding difficulties, intermittent fever, and abnormal neurology. Over time, up to 40% of patients develop chilblain lesions on toes, fingers, and occasionally ears, typically worse in winter.

Genetically, AGS results from mutations in genes encoding proteins involved in nucleic acid metabolism or sensing: TREX1 (3' repair exonuclease), the RNase H2 complex (RNASEH2A, RNASEH2B, RNASEH2C), SAMHD1 (deoxynucleoside triphosphate triphosphohydrolase), ADAR1 (adenosine deaminase acting on RNA), IFIH1 (cytosolic double-stranded RNA receptor MDA5), LSM11, and RNU7-1. The condition is under-diagnosed and occurs worldwide.

Reader's Guide

Aicardi–Goutières syndrome is significant as a model of how aberrant nucleic acid metabolism can trigger chronic type I interferon signaling, leading to neuroinflammation and autoimmunity. Studies of AGS-related proteins—TREX1, RNase H2, SAMHD1, ADAR1, and IFIH1—have revealed that inappropriate accumulation of self-derived nucleic acids can induce interferon production, linking the syndrome to both antiviral defense and autoimmune disease. The discovery that TREX1 can metabolize HIV-1 DNA and that SAMHD1 restricts retroelements has implications for understanding viral restriction and endogenous retroelement control. The condition's clinical overlap with in utero infection and systemic lupus erythematosus highlights shared pathogenic mechanisms. Although no therapies target the underlying cause, symptomatic treatments include tube-feeding, anticonvulsants, chilblain management, and physical therapy. The interferon signature—persistent elevation of interferon-stimulated gene transcripts in blood—serves as a diagnostic marker. AGS remains under-diagnosed, with at least 400 known cases as of 2014, and its variable severity underscores the importance of genetic counseling, given the 1 in 4 recurrence risk for most subtypes.

Did You Know?

• AGS is completely distinct from the similarly named Aicardi syndrome.
• The first international meeting on AGS was held in Pavia, Italy, in 2001.
• Mutations in RNASEH2B are the most frequent cause of AGS, accounting for the largest proportion of cases in a survey of 374 patients.
• Some individuals with AGS-related mutations are minimally affected, only showing chilblains, and attend mainstream education.

Clinical Spectrum: From Neonatal Onset to Mild Phenotypes

AGS manifests across a remarkably wide severity range. Roughly ten percent of cases emerge at or shortly after birth, presenting with microcephaly, neonatal seizures, poor feeding, jitteriness, cerebral calcifications, white matter abnormalities, and cerebral atrophy—signs that the pathological process was already active in utero. These neonatal infants may also display hepatosplenomegaly and thrombocytopaenia, a picture that closely resembles transplacental viral infection. Approximately one-third of these earliest-onset cases, particularly those tied to TREX1 mutations, do not survive past early childhood. The more frequent presentation arrives in early infancy, occasionally after a stretch of apparently typical development, with encephalopathic features such as irritability, persistent crying, feeding difficulties, unexplained intermittent fever, disturbed muscle tone, dystonia, an exaggerated startle response, and sometimes seizures. Glaucoma may be congenital or develop later; while many children retain normal vision, a significant proportion become cortically blind. Hearing is almost always intact. Over time, up to forty percent develop chilblain lesions on toes, fingers, and occasionally ears, typically flaring in winter. The original 1984 description portrayed AGS as uniformly fatal in childhood, but subsequent cases have revealed a far broader spectrum: some mutation carriers are minimally affected, perhaps only with chilblains, and attend mainstream school, while siblings sharing the same variant can show strikingly different severity.

Genetic Architecture and Inheritance Patterns

AGS is a genetically heterogeneous condition, with pathogenic variants now identified in at least nine different genes. The principal set comprises TREX1, a 3′ repair exonuclease; the three subunits of the ribonuclease H2 endonuclease complex (RNASEH2A, RNASEH2B, RNASEH2C); SAMHD1, a deoxynucleoside triphosphate triphosphohydrolase; ADAR1, which catalyses hydrolytic deamination of adenosine to inosine in double-stranded RNA; and IFIH1, encoding the cytosolic double-stranded RNA receptor MDA5. A survey of 374 diagnosed individuals identified RNASEH2B as the most frequently mutated gene. With the notable exceptions of IFIH1-related disease and rare TREX1 and ADAR1 cases, AGS follows an autosomal recessive pattern, so both parents are typically carriers and each subsequent pregnancy carries a one-in-four risk of an affected child. The OCLN gene on chromosome 5q13.2, associated with band-like cerebral calcification, has also been detected in affected individuals and classified as BLCPMG, a condition often co-occurring with AGS. Incomplete penetrance is a well-recognised feature: children within the same family carrying identical variants can display markedly divergent neurological and developmental trajectories. Genotype further shapes the clinical course, with TREX1 variants correlating with in utero onset and elevated mortality, whereas RNASEH2B variants tend to produce milder impairment, lower interferon activity, and a longer lifespan.

The Interferon Pathway and Molecular Mechanism

Type I interferon was first characterised more than fifty years ago as a soluble factor released by cells exposed to inactivated, non-replicating virus, capable of blocking subsequent live-virus infection. While the rapid induction and amplification of this system is highly adaptive for viral clearance, its aberrant stimulation or loss of regulatory control can drive inappropriate and excessive interferon output. In AGS, the implicated proteins—TREX1, the RNase H2 complex, SAMHD1, and ADAR1—all participate in nucleic acid processing and genomic surveillance. When their functions are disrupted, self-derived nucleic acids accumulate inappropriately and trigger type I interferon signalling. IFIH1 mutations add a further dimension, pointing to aberrant sensing of nucleic acids as an additional driver of immune upregulation. RNASEH2 specifically serves to remove misincorporated ribonucleotides from DNA during genome surveillance. In mouse models, loss of RNASEH2 activity produces neuroinflammation, cerebellar atrophy, and white matter defects that closely mirror the human disease. The emerging consensus is that the signalling of unrepaired DNA damage constitutes the fundamental upstream cause of the neurodegenerative features that define AGS.

Recognition, Diagnosis, and Global Understanding

The condition was first clinically described in 1984 through a report of eight cases, yet the formal name Aicardi–Goutières syndrome was not applied until 1992. The first dedicated international meeting on the disorder took place in Pavia, Italy, in 2001—nearly two decades after the initial clinical description. AGS has been identified in populations across the globe, but the true prevalence likely remains hidden because the condition is almost certainly under-diagnosed. By 2014, at least four hundred cases had been documented worldwide. Diagnostic confusion is compounded by the fact that AGS clinical features can closely mimic in utero acquired infection, and some characteristics overlap with systemic lupus erythematosus, both of which complicate differential diagnosis. The original 1984 characterisation portrayed AGS as a uniformly severe condition with unremitting neurological decline and childhood death. As more cases were identified over the following decades, this picture was substantially revised. Many patients now demonstrate a stable clinical course and remain alive into their fourth decade. The recognition of milder phenotypes, variable penetrance, and genotype-specific severity has transformed AGS from what was once considered a uniformly fatal diagnosis into a spectrum disorder demanding nuanced, individualised clinical management.